Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration
-
ADMA Biologics may have Misrepresented its Revenue Sources to Investors – Contact BFA Law about its Pending Securities Fraud Investigation
-
Merakris announces FDA Fast Track designation for MTX-001, its lead biologic candidate for the treatment of venous leg ulcers.
-
NeOnc (NASDAQ:NTHI) is developing therapies and delivery technologies targeting aggressive brain cancers and CNS-related conditions, and could be part of t
-
ADMA Biologics Investigated for Securities Fraud Over Channel Stuffing Allegations – Investors with Losses Notified to Contact BFA Law
-
Totaligent (OTCID: TGNT) forms JV with GloMed Solutions, a Japanese company with a proven distribution network in the Asia-Pacific region.
-
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services.
-
Did ADMA Biologics Mislead Investors about Alleged Channel Stuffing? BFA Law Notifies Investors with Losses of the Pending Securities Fraud Investigation
-
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services.
-
Valable pour la période 2025–2027, cet agrément permet aux entreprises innovantes françaises de faire appel à l’expertise d’Intravacc dans le développement de vaccins, le développement analytique et...